Nallathambi Naveenkumar, Bisaralli Rahul, Mamadapur Mahabaleshwar
Institute of Internal Medicine, Madras Medical College, Chennai, Tamilnadu, India.
Department of Clinical Immunology and Rheumatology, SDM College of Medical Sciences and Hospital, Dharwad, Karnataka, India.
Mediterr J Rheumatol. 2024 Sep 30;35(3):411-421. doi: 10.31138/mjr.010324.ies. eCollection 2024 Sep.
Limited studies summarise the immunomodulatory effects of SGLT2 inhibitors and Metformin in managing rheumatic diseases. The present narrative review aims to fill this knowledge gap by gathering information based on existing clinical evidence. A narrative review was conducted in November 2023 to identify studies investigating the impact of SGLT2 inhibitors and Metformin on rheumatic diseases. A literature search was performed across primary databases, including Medline/PubMed, Scopus, and Web of Science. Supplementary sources like Google Scholar, PubMed Central, Cochrane Library, and ScienceDirect were also consulted. Studies were screened for relevance, and those lacking pertinent outcome data were excluded. The review corroborates the multifaceted potential of Metformin as an adjunctive therapy in autoimmune rheumatologic conditions, offering avenues for further exploration and clinical application to enhance patient outcomes. However, limited literature exists on the clinical effects of SGLT2 inhibitors in rheumatic diseases.
仅有有限的研究总结了钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂和二甲双胍在治疗风湿性疾病中的免疫调节作用。本叙述性综述旨在通过基于现有临床证据收集信息来填补这一知识空白。2023年11月进行了一项叙述性综述，以确定研究SGLT2抑制剂和二甲双胍对风湿性疾病影响的研究。在包括Medline/PubMed、Scopus和Web of Science在内的主要数据库中进行了文献检索。还查阅了谷歌学术、PubMed Central、Cochrane图书馆和ScienceDirect等补充资源。对研究进行相关性筛选，排除那些缺乏相关结局数据的研究。该综述证实了二甲双胍作为自身免疫性风湿性疾病辅助治疗的多方面潜力，为进一步探索和临床应用提供了途径，以改善患者结局。然而，关于SGLT2抑制剂在风湿性疾病中的临床效果的文献有限。
